Arnold & Porter recently represented Aurobindo Pharma Limited in obtaining Federal Trade Commission (FTC) clearance for its acquisition of Lannett Company, Inc., a manufacturer of generic pharmaceutical products, in a transaction valued at approximately $250 million.
The transaction involved overlapping marketed and pipeline generic pharmaceutical products. Following the firm's advocacy before the FTC, the agency narrowed its competitive concerns to four products: mycophenolate mofetil oral suspension, niacin extended-release tablets, pilocarpine tablets, and rabeprazole sodium delayed-release tablets.
Arnold & Porter negotiated a consent agreement with the FTC under which Aurobindo agreed to divest those four products to Quagen Pharmaceuticals LLC, enabling the transaction to proceed. The FTC voted 2-0 to accept the consent agreement for public comment and granted early termination of the Hart-Scott-Rodino waiting period on June 18, 2026, permitting the acquisition to close.
The Arnold & Porter team was led by Antitrust partners Debbie Feinstein and David Emanuelson, counsel Barbara Wootton, and senior associate Andrew Ellingsen. Partner Betty Yan, co-head of the Life Sciences Transaction practice, also advised on the acquisition.